Computational prediction of the molecular mechanism of statin group of drugs against SARS-CoV-2 pathogenesis

被引:0
|
作者
Dipanjan Ghosh
Debabrata Ghosh Dastidar
Kamalesh Roy
Arnab Ghosh
Debanjan Mukhopadhyay
Nilabja Sikdar
Nidhan K. Biswas
Gopal Chakrabarti
Amlan Das
机构
[1] University of Calcutta,Department of Biotechnology, Dr. B. C. Guha Centre for Genetic Engineering and Biotechnology
[2] Guru Nanak Institute of Pharmaceutical Science and Technology,Department of Genetics
[3] Institute of Genetic Engineering,Human Genetics Unit, Kolmogorov Bhaban, Biological Sciences Division
[4] National Institute of Biomedical Genomics,undefined
[5] PO NSS,undefined
[6] Indian Statistical Institute,undefined
来源
关键词
D O I
暂无
中图分类号
学科分类号
摘要
Recently published clinical data from COVID-19 patients indicated that statin therapy is associated with a better clinical outcome and a significant reduction in the risk of mortality. In this study by computational analysis, we have aimed to predict the possible mechanism of the statin group of drugs by which they can inhibit SARS-CoV-2 pathogenesis. Blind docking of the critical structural and functional proteins of SARS-CoV-2 like RNA-dependent RNA polymerase, M-protease of 3-CL-Pro, Helicase, and the Spike proteins ( wild type and mutants from different VOCs) were performed using the Schrodinger docking tool. We observed that fluvastatin and pitavastatin showed fair, binding affinities to RNA polymerase and 3-CL-Pro, whereas fluvastatin showed the strongest binding affinity to the helicase. Fluvastatin also showed the highest affinity for the SpikeDelta and a fair docking score for other spike variants. Additionally, molecular dynamics simulation confirmed the formation of a stable drug-protein complex between Fluvastatin and target proteins. Thus our study shows that of all the statins, fluvastatin can bind to multiple target proteins of SARS-CoV-2, including the spike-mutant proteins. This property might contribute to the potent antiviral efficacy of this drug.
引用
收藏
相关论文
共 50 条
  • [31] Evaluating cepharanthine analogues as natural drugs against SARS-CoV-2
    Hijikata, Atsushi
    Shionyu-Mitsuyama, Clara
    Nakae, Setsu
    Shionyu, Masafumi
    Ota, Motonori
    Kanaya, Shigehiko
    Hirokawa, Takatsugu
    Nakajima, Shogo
    Watashi, Koichi
    Shirai, Tsuyoshi
    FEBS OPEN BIO, 2022, 12 (01): : 285 - 294
  • [32] Candidate drugs against SARS-CoV-2 and COVID-19
    McKee, Dwight L.
    Sternberg, Ariane
    Stange, Ulrike
    Laufer, Stefan
    Naujokat, Cord
    PHARMACOLOGICAL RESEARCH, 2020, 157
  • [33] Antivirals Against Coronaviruses: Candidate Drugs for SARS-CoV-2 Treatment?
    Santos, Igor de Andrade
    Grosche, Victoria Riquena
    Goulart Bergamini, Fernando Rodrigues
    Sabino-Silva, Robinson
    Gomes Jardim, Ana Carolina
    FRONTIERS IN MICROBIOLOGY, 2020, 11
  • [34] Antiparasitic Drugs against SARS-CoV-2: A Comprehensive Literature Survey
    Calvo-Alvarez, Estefania
    Dolci, Maria
    Perego, Federica
    Signorini, Lucia
    Parapini, Silvia
    D'Alessandro, Sarah
    Denti, Luca
    Basilico, Nicoletta
    Taramelli, Donatella
    Ferrante, Pasquale
    Delbue, Serena
    MICROORGANISMS, 2022, 10 (07)
  • [35] SARS-CoV-2: Some Aspects of Molecular Evolution, Cellular Pathogenesis, and Immune System Mechanism Elusion
    Quirino, Angela
    Marascio, Nadia
    Barreca, Giorgio Settimo
    Gallo, Luigia
    Giancotti, Aida
    Lamberti, Angelo Giuseppe
    Peronace, Cinzia
    Trecarichi, Enrico Maria
    Fusco, Paolo
    Mazzitelli, Maria
    Divenuto, Francesca
    Pavia, Grazia
    Suraci, Angela
    Matera, Giovanni
    Liberto, Maria Carla
    APPLIED SCIENCES-BASEL, 2021, 11 (24):
  • [36] Molecular Mechanism of Evolution and Human Infection with SARS-CoV-2
    He, Jiahua
    Tao, Huanyu
    Yan, Yumeng
    Huang, Sheng-You
    Xiao, Yi
    VIRUSES-BASEL, 2020, 12 (04):
  • [37] Computational repurposing of asthma drugs as potential inhibitors of SARS-CoV-2 Mpro
    Hussain, A.
    NEW MICROBES AND NEW INFECTIONS, 2022, 47
  • [38] Computational study on the affinity of potential drugs to SARS-CoV-2 main protease
    Martin, Veronica
    Sanz-Novo, Miguel
    Leon, Iker
    Redondo, Pilar
    Largo, Antonio
    Barrientos, Carmen
    JOURNAL OF PHYSICS-CONDENSED MATTER, 2022, 34 (29)
  • [39] Computational screening of antagonists against the SARS-CoV-2 (COVID-19) coronavirus by molecular docking
    Yu, Ran
    Chen, Liang
    Lan, Rong
    Shen, Rong
    Li, Peng
    INTERNATIONAL JOURNAL OF ANTIMICROBIAL AGENTS, 2020, 56 (02)
  • [40] Inhibitory potential of repurposed drugs against the SARS-CoV-2 main protease: a computational-aided approach
    Fadaka, Adewale Oluwaseun
    Aruleba, Raphael Taiwo
    Sibuyi, Nicole Remaliah Samantha
    Klein, Ashwil
    Madiehe, Abram Madimabe
    Meyer, Mervin
    JOURNAL OF BIOMOLECULAR STRUCTURE & DYNAMICS, 2022, 40 (08): : 3416 - 3427